The European Association of Nuclear Medicine (EANM) has highlighted the goals and plans of the new Presidency of the Council of the EU with significant relevance to nuclear medicine and radiopharmaceuticals.
The presidency of the Council rotates among the EU member states every six months, and on 1 July, Denmark assumed the rotating role. In its official program for the six-month term, the Danish presidency outlines a strong focus on health resilience, pharmaceutical reform, and life sciences innovation, the EANM said in a post.
Specifically, the presidency plans to advance negotiations on the EU pharmaceutical package and the Critical Medicines proposal, both designed to enhance the EU’s strategic autonomy and reduce external dependencies. These efforts are directly relevant to radiopharmaceuticals, which are often dependent on fragile, cross-border supply chains and short production timelines, the EANM noted.
In addition, the presidency’s support for the development of a new EU Life Science Strategy signals renewed investment in scientific innovation, according to the EANM.
“The translation of research into clinical practice remains a major challenge for our field, and policy frameworks that address regulatory timelines, clinical trial infrastructure, and workforce development would provide significant benefits,” the EANM noted.
Overall, the Danish presidency’s agenda addresses many of the underlying policy gaps affecting the field, from supply chain resilience to investment in innovation, and offers an opportunity to ensure radiopharmaceuticals are recognized as critical tools in the EU’s health strategy, the association added.
“We will continue to follow and contribute to these discussions throughout the presidency,” the EANM said.
